Search Result

Results for "

acute heart failure

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Adrenergic Receptor (1) Akt (3) AMPK (2) Angiotensin Receptor (2) Angiotensin-converting Enzyme (ACE) (6) Apoptosis (2) Arrestin (2) Autophagy (4) Calcium Channel (4) Casein Kinase (2) Drug Metabolite (1) Endogenous Metabolite (1) FXR (1) Guanylate Cyclase (2) Isotope-Labeled Compounds (1) mTOR (1) Natriuretic Peptide Receptor (NPR) (1) NF-κB (2) Phosphodiesterase (PDE) (2) PKC (1) Potassium Channel (2) Reference Standards (7) RXFP Receptor (1) SARS-CoV (4) STAT (1) TGF-beta/Smad (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (24) Endocrinology (1) Infection (1) Inflammation/Immunology (2) Metabolic Disease (3) Neurological Disease (8)

By Targets:

Adenosine Receptor (2)

Adrenergic Receptor (1)

Akt (3)

AMPK (2)

Angiotensin Receptor (2)

Angiotensin-converting Enzyme (ACE) (6)

Apoptosis (2)

Arrestin (2)

Autophagy (4)

Calcium Channel (4)

Casein Kinase (2)

Drug Metabolite (1)

Endogenous Metabolite (1)

FXR (1)

Guanylate Cyclase (2)

Isotope-Labeled Compounds (1)

mTOR (1)

Natriuretic Peptide Receptor (NPR) (1)

NF-κB (2)

Phosphodiesterase (PDE) (2)

PKC (1)

Potassium Channel (2)

Reference Standards (7)

RXFP Receptor (1)

SARS-CoV (4)

STAT (1)

TGF-beta/Smad (2)

By Research Areas:

Cancer (7)

Cardiovascular Disease (24)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (3)

Neurological Disease (8)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0119

Nitroprusside disodium dihydrate Maximum Cited Publications 17 Publications Verification Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate	Autophagy	Cardiovascular Disease Cancer
Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) is a vasodilator that available for the research of acute hypertension, heart failure. Nitroprusside disodium dehydrate induces autophagy in glutathione-depleted osteoblasts. Nitroprusside disodium dehydrate acts as a nitric oxide (NO) donor in a rat intestinal ischemia reperfusion model .

HY-14286

Levosimendan 2 Publications Verification Simsndan; OR-1259	Potassium Channel Phosphodiesterase (PDE) Autophagy	Cardiovascular Disease
Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.

HY-N0559

Kirenol 1 Publications Verification	Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis .

HY-14181

Cinaciguat 4 Publications Verification BAY 58-2667	Guanylate Cyclase	Cardiovascular Disease
Cinaciguat is an activator of guanylate cyclase (sGC), and used for acute decompensated heart failure.

HY-A0115

Ramiprilat HOE 498 diacid; Ramipril diacid	Drug Metabolite Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease
Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a K_i value of 7 pM. Ramiprilat has acute antlhypertensive effect. Ramiprilat can be used for high blood pressure and heart failure research .

HY-N0712

Typhaneoside 3 Publications Verification	Autophagy mTOR Akt FXR	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Typhaneoside is an orally bioavailable signal modulator and cellular regulator. Typhaneoside regulates the PI3K/Akt/mTOR autophagy transduction pathway. Typhaneoside promotes the activation of AMP-activated protein kinase and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, and cell cycle arrest at the G₂/M phase, and reduces cancer cell viability. Typhaneoside activates the farnesoid X receptor signaling pathway, improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside is applicable to research related to post-myocardial infarction heart failure, acute myeloid leukemia, non-alcoholic fatty liver disease, and neurological disorders .

HY-P2141

TRV-120027 3 Publications Verification TRV027	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-12502A

Efonidipine hydrochloride monoethanolate 1 Publications Verification NZ-105 hydrochloride monoethanolate; (±)-Efonidipine hydrochloride monoethanolate	Calcium Channel SARS-CoV	Cardiovascular Disease Neurological Disease Cancer
Efonidipine (NZ-105) hydrochloride monoethanolate is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride monoethanolate inhibits SARS-CoV-2 main protease. Efonidipine hydrochloride monoethanolate modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride monoethanolate reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride monoethanolate improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride monoethanolate can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-B0384

Temocapril hydrochloride 2 Publications Verification	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-12502

Efonidipine 1 Publications Verification NZ-105; (±)-Efonidipine	Calcium Channel SARS-CoV	Cardiovascular Disease Neurological Disease Cancer
Efonidipine (NZ-105) is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine inhibits SARS-CoV-2 main protease. Efonidipine modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine reduces plasma aldosterone levels in vivo. Efonidipine improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-100713

Temocapril 2 Publications Verification	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-10965

Rolofylline KW-3902	Adenosine Receptor	Neurological Disease
Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP₄₅₀) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .

HY-119817

Flosequinan BTS 49465; Flosequinon	PKC	Cardiovascular Disease
Flosequinan is a balanced vasodilator. Flosequinan not only significantly reduces systemic vascular resistance, but also significantly reduces the beating component of left ventricular afterload, characteristic impedance and arterial wave reflection, which can be used in the research of acute heart failure .

HY-14286R

Levosimendan (Standard) Simsndan (Standard); OR-1259 (Standard)	Reference Standards Potassium Channel Phosphodiesterase (PDE) Autophagy	Cardiovascular Disease
Levosimendan (Standard) is the analytical standard of Levosimendan. This product is intended for research and analytical applications. Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.

HY-120521

Urodilatin	Natriuretic Peptide Receptor (NPR)	Neurological Disease
Urodilatin is an analogue of ANF-(99-126). Urodilatin is a diuretic-natriuretic regulatory peptide. Urodilatin can be used for research of acute renal failure, congestive heart failure, and bronchial asthma, etc .

HY-12502B

Efonidipine hydrochloride NZ-105 hydrochloride; (±)-Efonidipine hydrochloride	Calcium Channel SARS-CoV	Cardiovascular Disease Cancer
Efonidipine (NZ-105) hydrochloride is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride inhibits SARS-CoV-2 main protease. Efonidipine hydrochloride modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-P11041

VS-IP1	STAT	Cardiovascular Disease
VS-IP1 is an interfering peptide that blocks viperin-mediated STAT1 degradation, thereby preventing coxsackievirus B3 (CVB3)-induced acute heart failure (AHF) .

HY-100713R

Temocapril (Standard)	Reference Standards Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril (Standard) is the analytical standard of Temocapril. This product is intended for research and analytical applications. Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-14181R

Cinaciguat (Standard) BAY 58-2667 (Standard)	Guanylate Cyclase Reference Standards	Cardiovascular Disease
Cinaciguat (Standard) is the analytical standard of Cinaciguat. This product is intended for research and analytical applications. Cinaciguat is an activator of guanylate cyclase (sGC), and used for acute decompensated heart failure.

HY-100713S

Temocapril-d5	Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Temocapril-d₅ is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-12502AR

Efonidipine hydrochloride monoethanolate (Standard) NZ-105 hydrochloride monoethanolate (Standard); (±)-Efonidipine hydrochloride monoethanolate (Standard)	Reference Standards Calcium Channel SARS-CoV	Cardiovascular Disease
Efonidipine (NZ-105) hydrochloride monoethanolate (Standard) is the analytical standard of Efonidipine hydrochloride monoethanolate (HY-12502AR). This product is intended for research and analytical applications. Efonidipine (NZ-105) hydrochloride monoethanolate is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride monoethanolate inhibits SARS-CoV-2 main protease. Efonidipine hydrochloride monoethanolate modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride monoethanolate reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride monoethanolate improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride monoethanolate can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-10965R

Rolofylline (Standard) KW-3902 (Standard)	Adenosine Receptor Reference Standards	Neurological Disease
Rolofylline (Standard) is the analytical standard of Rolofylline. This product is intended for research and analytical applications. Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .

HY-N0559R

Kirenol (Standard)	Reference Standards Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Kirenol (Standard) is the analytical standard of Kirenol (HY-N0559). This product is intended for research and analytical applications. Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis.

HY-B0384R

Temocapril hydrochloride (Standard)	Angiotensin-converting Enzyme (ACE) Reference Standards	Cardiovascular Disease
Temocapril (hydrochloride) (Standard) is the analytical standard of Temocapril (hydrochloride). This product is intended for research and analytical applications. Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .

HY-P11625

R9-13	RXFP Receptor	Cardiovascular Disease
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .

HY-112071A

Prenalterol hydrochloride	Adrenergic Receptor	Endocrinology
Prenalterol hydrochloride is a partial adrenal agonist with functional β1-receptor specificity and positive inotropic effects. Prenalterol hydrochloride is effective in suppressing acute heart failure, low output syndrome after myocardial infarction, shock, and reducing orthostatic hypotension in Shy-Drager syndrome .

Cat. No.	Product Name	Target	Research Area